图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
真核基因表达评论综述™
影响因子: 1.841 5年影响因子: 1.927 SJR: 0.627 SNIP: 0.516 CiteScore™: 1.96

ISSN 打印: 1045-4403
ISSN 在线: 2162-6502

真核基因表达评论综述™

DOI: 10.1615/CritRevEukaryotGeneExpr.2018025121
pages 373-384

Interferon-Free Regimen for Hepatitis C: Insight and Management

Muhammad Shareef Masoud
Department of Bioinformatics and Biotechnology, Government College University Faisalabad (GCUF), Pakistan
Usman Ali Ashfaq
Department of Bioinformatics & Biotechnology, Government College University, 38000 Faisalabad, Pakistan
Hina Khalid
Department of Bioinformatics and Biotechnology, Government College University Faisalabad (GCUF), Pakistan

ABSTRACT

The rapid development of direct-acting antiviral agents (DAA) for hepatitis C virus (HCV) therapy dramatically altered the treatment landscape of this disease. The DAA regimen is associated with various advantages including high sustained virological response (SVR) with minimum side effects and low pill load and specific inhibition of viral replication, which lowers dependence on the host cell. This regimen has substantially replaced conventional (interferon) therapy with high cure rates (> 90%) in most HCV populations. This review provides insight into clinical studies of NS3/4A protease inhibitors, NS5B viral polymerase inhibitor (nucleotide and non-nucleotide), and NS5A inhibitors, alone and in combination.


Articles with similar content:

Role of Toll-Like Receptors in Hepatitis C Virus Pathogenesis and Treatment
Critical Reviews™ in Eukaryotic Gene Expression, Vol.26, 2016, issue 4
Saba Khaliq, Usman Ali Ashfaq, Muhammad Sarfaraz Iqbal
COMMENTARY. Regulation of Drug and Immune Resistance by YY1 in Cancer
Forum on Immunopathological Diseases and Therapeutics, Vol.1, 2010, issue 1-2
James A. McCubrey, Maria C. Mazzarino, Natale D'Alessandro
The Role of HSP70 in the Diagnosis of HCC
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 3-4
Gabriele Multhoff, Lydia Giannitrapani
Current Status of Radiosensitizing Agents for the Management of Rectal Cancer
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 4
Henrik Illum
Biology of Rectal Cancer−The Rationale for Targeted Therapy
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 4
Sean Dineen